Immuno-Oncology Market to Hit Billions of Dollars in Years to Come, Projects RNCOS in Its New Research Report Published at MarketPublishers.com
07 Apr 2017 • by Natalie Aster
LONDON – Over the recent past, the immuno-oncology market has seen a range of advances. The level of the competition between the market participants gets more and more intensified. The biotech and pharma companies are seeking to achieve first-mover advantage by introducing novel and the most effective treatment options. This therapy is poised to be a game-changing approach to cancer treatment.
The worldwide immuno-oncology market is an essential and rapidly emerging field, expected to rack up billions of dollars in revenue over the next five to ten years.
With respect to the various major product classes, monoclonal antibodies accounted for the largest share as of 2016 owing to surging prevalence of cancer and growing application in a range of therapies.
By application, lung cancer and melanoma dominate the market, with several firms and research institutions laying emphasis on new therapy approaches, thus making the vital contribution to the immuno-oncology market on a global level.
As of 2016, the North American region grabbed the largest share of the marketplace.
Amid the key players operating in the market one can name Bristol-Myers Squibb, Amgen, Merck, and F. Hoffmann-La Roche.
New research report “Immuno-Oncology Market - Global Forecast to 2022” elaborated by RNCOS E-Services offers a detailed analysis of the present-day and future market development path of the market alongside giving with a snapshot of the industry.
The study sheds light on the main drivers and challenges, in tandem with canvassing the latest developments and trends that shape the growth of the industry. Additionally, the report sheds light on the various opportunities for growth and expansion of the worldwide immuno-oncology market. It provides an all-round analysis of the sales of key marketed immuno-oncology drug products. The report provides an analysis and forecast of key indications to 2022. It discusses the current clinical trials for innovative product development, covering the immuno-oncology programmes at various clinical trial stages, different aspects of the clinical trials, etc.; outlines the strategic collaborations amongst the players for boosting their market share. Furthermore, the report discusses some of the leading players in the immuno-oncology market.
Other insightful market reports by RNCOS E-Services are available at the publisher's page at MarketPublishers.com.